The before-and-after photo appears first. Then the comment section erupts. Then the DMs start flooding in asking: what is she on? And somewhere in that sequence — between the influencer’s glowing skin and the 47,000 likes — someone decides to order a vial of something they can barely pronounce, shipped in a small refrigerated box from an online pharmacy they found through a sponsored post.
This is how the injectable peptide market works in 2026. Not through doctors’ offices or formal consultations, but through the machinery of social media aspiration, delivered directly to the door. Influencers have been calling these compounds the “glow up potion” they never knew they needed — products claiming to boost collagen, accelerate fat loss, improve sleep, brighten skin, and essentially rewire the body’s biology from the outside in. The appeal is obvious. The risks are considerably less photogenic.
| Category | Details |
|---|---|
| Topic | Unapproved injectable peptides marketed online as wellness and “glow up” products |
| Products Involved | Compounded injectables including peptides, NAD, tanning agents, and tirzepatide-B12 combinations |
| Key Company Warning | Eli Lilly issued a public letter warning that compounded tirzepatide mixed with vitamin B12 contains significant levels of an unknown chemical impurity |
| Regulatory Body | U.S. Food and Drug Administration (FDA) — these compounded combinations are not FDA-regulated |
| Approved Tirzepatide Brands | Mounjaro (type 2 diabetes) and Zepbound (weight loss) — both by Eli Lilly |
| Sales Scale | Lilly’s tirzepatide brands generated $36.5 billion in global sales in 2025 |
| Known Risks | Impurity from tirzepatide-B12 reaction may introduce toxicity, immune reactions, or reduce drug efficacy — long-term effects unknown |
| Industry Criticism | Scott Brunner, CEO of the Alliance for Pharmacy Compounding, says Lilly has not disclosed enough detail about sample sources or impurity magnitude for independent verification |
| Who Is Selling | Telehealth companies, medical spas, compounding pharmacies — often leveraging regulatory loopholes for mass-marketing |
| Consumer Risk Profile | People injecting unapproved peptides at home, sometimes guided only by influencer content or online tutorials |
| Legal Context | Novo Nordisk and Eli Lilly have both filed legal actions against compounding companies; Hims & Hers reached a separate partnership with Novo to resolve semaglutide dispute |
| Expert Position | Medical professionals broadly advise against any unapproved injectable used outside clinical supervision |
What’s actually inside those vials is where things get uncomfortable. Eli Lilly, whose blockbuster weight-loss drug tirzepatide generated an almost staggering $36.5 billion in global sales last year, recently issued a public warning after testing compounded versions of tirzepatide that had been mixed with vitamin B12 — a popular combination being sold by telehealth companies, medical spas, and compounding pharmacies across the country. The results weren’t reassuring. Lilly’s tests found significant levels of an impurity created by a direct chemical reaction between tirzepatide and B12. What that impurity actually does to the human body over time? Nobody knows. Including, notably, Lilly itself, which admitted in its open letter that “nothing is known” about the short- or long-term effects of this interaction in people.
It’s hard not to sit with that phrase for a moment. A major pharmaceutical company, one with enormous resources and every incentive to understand its own flagship product, is openly saying the effects are unknown. And yet the products keep shipping.
The compounding pharmacy industry, to be fair, has pushed back. Scott Brunner, who leads the Alliance for Pharmacy Compounding, has pointed out that Lilly hasn’t disclosed nearly enough about the source of the samples it tested, how they were stored, or the precise nature and scale of the impurity, making it genuinely difficult for anyone outside the company to independently evaluate the claim. That’s a legitimate criticism. The problem is it doesn’t resolve the underlying question, which is: what, exactly, are people injecting into themselves when they order these blended compounds from a telehealth app at midnight? The answer, with uncomfortable regularity, is that they don’t fully know.
The broader injectable wellness space runs far beyond tirzepatide. Peptides marketed under names that sound somewhere between a laboratory catalog and a luxury skincare line are being touted online for everything from immune support to anti-aging to what one widely shared post described as “becoming ungovernable, in a hot way.” NAD peptides, tanning injections, whitening agents — there’s an entire category of products being injected into bodies with no FDA oversight, no standardized dosing, and no long-term safety data. Some people are doing this at home, guided by tutorial videos, in kitchens and bathrooms, using syringes ordered alongside the compounds themselves. Watching that reality take shape feels somewhere between fascinating and genuinely alarming.
There’s a structural problem here that cosmetic warnings alone won’t fix. The FDA has been stepping up enforcement in recent months, targeting companies that mass-market compounded drugs using regulatory loopholes designed for custom, individual prescriptions — not bulk commercial production. Hims & Hers, the prominent telehealth platform, recently settled a legal dispute with Novo Nordisk over compounded semaglutide through a partnership arrangement, suggesting the industry is slowly recalibrating under pressure. But the pace of that recalibration is slow relative to how fast these products move through social media pipelines.
The influencer ecosystem accelerates everything. By the time a warning reaches a consumer, the product has already been seen by hundreds of thousands of people, recommended in comment sections, referenced in YouTube videos, and ordered in bulk by people who found a discount code. The before-and-after photo does a lot of work. Regulatory language does comparatively little.
It’s possible that some of these compounds, under proper clinical supervision and rigorous testing, could eventually prove useful. Medicine has a long history of unconventional treatments that took time to find their proper context. But that’s a very different situation from an unsupervised person injecting a compound of uncertain composition into their abdomen because a TikTok creator has very good lighting and said it changed her life. There’s a feeling, watching this market grow, that the reckoning hasn’t fully arrived yet — and that when it does, the “glow up” framing will seem, in retrospect, like a particularly poor choice of words.
